Novo Nordisk and Sanofi are among the companies which have been presenting data on their investigational and already-marketed drugs at the American Diabetes Association conference in Philadelphia. First up, Novo reported results comparing degludec, its ultra-long-acting insulin, with Sanofi’s Lantus (insulin glargine), the world’s biggest-selling insulin product. The Phase IIIa 1,030-patient study showed that degludec significantly reduced the rate of hypoglycaemia at night in adults with type 2 diabetes.
